The objective of this study was to use a large population database to explore whether clinicopathologic variables and pCR rates vary based on HER2 IHC status among patients with HER2+ breast cancer undergoing NT anti-HER2 therapy followed by surgery. Here, ERBB2 is linked to breast cancer.